Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-03-15-Speech-4-128"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-03-15"^^xsd:date2
dcterms:Is Part Of	lp_eu:Access to medicaments for AIDS patients in the third world2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20010315.7.4-128"2
lpv:hasSubsequent	lp_eu:2001-03-15-Speech-4-1292
lpv:speaker	lp:Paul A.A.J.G. Lannoye2
lpv:spokenAs	unknown; Ecolo (1999-07-20--2004-07-19)3 member; Conference of Presidents (1999-07-20--2002-01-07)3 chair; G/EFA (1999-07-20--2002-01-07)3 substitute; Committee on the Environment, Public Health and Consumer Policy (1999-07-22--2002-01-14)3 member; Members from the European Parliament to the Joint Parliamentary Assembly of the Agreement between the African, Caribbean and Pacific States and the European Union (ACP-EU) (1999-09-14--2002-01-14)3 substitute; Temporary committee on human genetics and other new technologies in modern medicine (2000-12-13--2001-11-29)3 member; Committee on Development and Cooperation (1999-07-21--2002-01-14)3
lpv:translated text	"Mr President, I feel that we can be satisfied - at least my group is satisfied - that not only is this debate being held at an important juncture when a process is under way to mobilise the international press, a process which has currently been suspended in South Africa, but it also has a symbolic value: do poor communities have priority access to medication which can relieve their suffering and delay their death or not? This is a fundamental problem and I am doubly delighted that the main groups in Parliament have agreed on a joint text which sends out a very strong message. The first message is directed at the pharmaceutical industries, calling on them to withdraw their case against South Africa, which is important, and the second message is that we want a clear interpretation within the framework of the TRIPS agreement on intellectual property, or even for the agreement to be revised. We must certainly welcome the fact that the European Commission, represented by Mr Lamy, has undertaken to pursue this course and I therefore subscribe to what the previous speakers have said. One last figure to conclude: as far as AIDS is concerned, patented drugs cost about one hundred times more than generic drugs, which have the same effect but which are manufactured in countries where patents are not yet the norm. This applies to India in particular. This should make us seriously aware of the advantages of having a system to protect intellectual property in an area such as this, where it is vital for people to have access to medication. I think that this process will re-launch the debate, as will the interesting position to be taken by the European Parliament."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph